Palivizumab, a monoclonal antibody is used for the prophylaxis of:
**Core Concept**
Palivizumab is a monoclonal antibody that targets respiratory syncytial virus (RSV) and is used for the prevention of serious lower respiratory tract disease caused by RSV in high-risk infants.
**Why the Correct Answer is Right**
Palivizumab works by binding to the RSV fusion protein, preventing it from fusing with the host cell membrane and thereby inhibiting viral entry and replication. This mechanism of action is crucial in preventing severe disease in high-risk infants, such as those with underlying heart or lung disease, premature infants, or infants with chronic lung disease.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as palivizumab is not used for the prophylaxis of influenza or other viral infections. While influenza is a significant cause of respiratory illness in infants, palivizumab is specifically targeted against RSV.
**Option B:** This option is incorrect as palivizumab is not used for the treatment of established RSV infection. Instead, it is used for prophylaxis to prevent severe disease in high-risk infants.
**Option C:** This option is incorrect as palivizumab is not used for the prevention of bacterial infections. While bacterial infections can also cause respiratory illness in infants, palivizumab is specifically targeted against RSV.
**Clinical Pearl / High-Yield Fact**
Palivizumab is administered monthly during the RSV season, typically from November to March in the Northern Hemisphere, to high-risk infants. This timing is critical in maximizing the benefit of prophylaxis and preventing severe disease.
**Correct Answer: C.** Respiratory syncytial virus (RSV) infection in high-risk infants.